Protein-level analysis revealed significantly decreased FCN1 levels in BRCA, Ovarian serous cystadenocarcinoma (OV), Lung adenocarcinoma (LUAD), and Liver hepatocellular carcinoma (LIHC), whereas it was significantly elevated in COAD, clear cell renal cell carcinoma (ccRCC), Uterine Corpus Endometrial Carcinoma (UCEC), Pancreatic adenocarcinoma (PAAD), Head and Neck squamous cell carcinoma (HNSC), and Glioblastoma multiforme (GBM) (Figure 1E). This evidence concerns the gene FCN1 and pancreatic adenocarcinoma.